Two cases of cidofovir overdose have been reported. These patients received single doses of VISTIDE (cidofovir) at 16.3 mg/kg and 17.4 mg/kg, respectively, with concomitant oral probenecid and intravenous hydration. In both cases, the patients were hospitalized and received oral probenecid (one gram three times daily) and vigorous intravenous hydration with normal saline for 3 to 5 days. Significant changes in renal function were not observed in either patient.

Initiation of therapy with VISTIDE (cidofovir) is contraindicated in patients with a serum creati-nine > 1.5 mg/dL, a calculated creatinine clearance ≤ 55 mL/min, or a urine protein ≥ 100 mg/dL (equivalent to ≥ 2+ proteinuria).

VISTIDE (cidofovir) is contraindicated in patients receiving agents with nephrotoxic potential. Such agents must be discontinued at least seven days prior to starting therapy with VISTIDE (cidofovir)

VISTIDE (cidofovir) is contraindicated in patients with hypersensitivity to cidofovir.

VISTIDE (cidofovir) is contraindicated in patients with a history of clinically severe hypersensitiv- 102 ity to probenecid or other sulfa-containing medications.

Direct intraocular injection of VISTIDE is contraindicated; direct injection of cidofovir has been associated with iritis, ocular hypotony, and permanent impairment of vision.

Last reviewed on RxList: 8/14/2008
This monograph has been modified to include the generic and brand name in many instances.